CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $300,482 | -19.2% | 6,620 | -0.1% | 0.04% | -25.0% |
Q2 2023 | $371,871 | +14.6% | 6,624 | -7.7% | 0.05% | +8.3% |
Q1 2023 | $324,480 | +1.4% | 7,174 | -8.9% | 0.05% | -4.0% |
Q4 2022 | $320,078 | -56.0% | 7,874 | -29.2% | 0.05% | -58.3% |
Q3 2022 | $727,000 | +5.7% | 11,124 | -1.8% | 0.12% | +9.1% |
Q2 2022 | $688,000 | -3.6% | 11,324 | -0.4% | 0.11% | +15.8% |
Q1 2022 | $714,000 | -39.4% | 11,374 | -26.8% | 0.10% | -36.2% |
Q4 2021 | $1,178,000 | -34.5% | 15,544 | -3.3% | 0.15% | -38.9% |
Q3 2021 | $1,799,000 | -32.2% | 16,074 | -2.0% | 0.24% | -32.0% |
Q2 2021 | $2,654,000 | +35.8% | 16,394 | +2.2% | 0.36% | +22.1% |
Q1 2021 | $1,955,000 | -16.9% | 16,044 | +4.4% | 0.29% | -22.0% |
Q4 2020 | $2,353,000 | +97.6% | 15,368 | +7.9% | 0.38% | +65.4% |
Q3 2020 | $1,191,000 | +16.1% | 14,248 | +2.1% | 0.23% | +4.6% |
Q2 2020 | $1,026,000 | +134.8% | 13,959 | +35.5% | 0.22% | +84.7% |
Q1 2020 | $437,000 | -24.5% | 10,303 | +8.5% | 0.12% | -11.3% |
Q4 2019 | $579,000 | – | 9,499 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |